Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.46 |
| ▸ | PGK2 | P07205 | 1/20 | 0.46 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.37 |
| ▸ | KDM4A | O75164 | 2/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.37 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.37 |
| ▸ | TET3 | O43151 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL838758 | 1.00 | PGK1 (0.46) | PGK1PGK2OR51E2TP53SMN1; SMN2 | |
| SCHEMBL20703280 | 1.00 | PGK1 (0.46) | PGK1PGK2OR51E2TP53SMN1; SMN2 | |
| SCHEMBL3422576 | 0.77 | GABRR1 (0.42) | TP53HPGDHTT | |
| SCHEMBL838795 | 0.76 | SMN1; SMN2 (0.38) | SMN1; SMN2HPGDHTT | |
| SCHEMBL840194 | 0.76 | SMN1; SMN2 (0.38) | SMN1; SMN2HPGDHTT | |
| SCHEMBL838796 | 0.76 | SMN1; SMN2 (0.38) | SMN1; SMN2HPGDHTT | |
| Acetic Acid SCHEMBL3254339 | 0.75 | MAPK1 (0.42) | TP53SMN1; SMN2HPGDHTT | |
| SCHEMBL29115716 | 0.75 | ALDH1A1 (0.39) | HPGD | |
| SCHEMBL29115715 | 0.75 | ALDH1A1 (0.39) | HPGD | |
| SCHEMBL7392053 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3661921-B1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NODTHERA LTD (GB) | 2023-10-18 | — | — | EP | disclosed |
| US-20210087147-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NodThera Limited (GB) | 2021-03-25 | — | — | US | disclosed |
| EP-3661921-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | Nodthera Limited (GB) | 2020-06-10 | — | — | EP | disclosed |
| WO-2019025467-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NodThera Limited (GB) | 2019-02-07 | — | — | WO | disclosed |
| EP-0535042-B1 | ANGIOTENSIS CONVERTING ENZYME INHIBITORS | FISONS PLC (GB) | 1995-03-29 | — | — | EP | disclosed |
| US-5348978-A | Angiotensin converting enzyme inhibitors | FISONS PLC (GB) | 1994-09-20 | — | — | US | disclosed |
| EP-0535042-A1 | ANGIOTENSIS CONVERTING ENZYME INHIBITORS. | FISONS PLC (GB) | 1993-04-07 | — | — | EP | disclosed |
| WO-1992000276-A2 | ANGIOTENSIS CONVERTING ENZYME INHIBITORS | FISONS PLC (GB) | 1992-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087147-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, NOD1, NLRP1 | PGK1 2674/4885PGK2 3763/4885OR51E2 4592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.